posted on 2013-11-08, 00:00authored byAlex de Voux, Anne C. Spaulding, Curt Beckwith, Ann Avery, Chyvette Williams, Lauren C. Messina, Sarah Ball, Frederick L. Altice
Background: Although routine HIV testing is recommended for jails, little empirical data exist describing newly diagnosed
individuals in this setting.
Methods: Client-level data (CLD) are available on a subset of individuals served in EnhanceLink, for the nine of the 10 sites
who enrolled newly diagnosed persons in the client level evaluation. In addition to information about time of diagnosis, we
analyzed data on initial CD4 count, use of antiretroviral therapy (ART), and linkage to care post discharge. Baseline data from
newly diagnosed persons were compared to data from persons whose diagnoses predated jail admission.
Results: CLD were available for 58 newly diagnosed and 708 previously diagnosed individuals enrolled between 9/08 and 3/
11. Those newly diagnosed had a significantly younger median age (34 years) when compared to those previously
diagnosed (41 years). In the 30 days prior to incarceration, 11% of those newly diagnosed reported injection drug use and
29% reported unprotected anal intercourse. Median CD4 count at diagnosis was 432 cells/mL (range: 22–1,453 cells/mL). A
minority (21%, N = 12) of new diagnoses started antiretroviral treatment (ART) before release; 74% have evidence of linkage
to community services.
Conclusion: Preliminary results from a cross-sectional analysis of this cohort suggest testing in jails finds individuals early on
in disease progression. Most HIV+ detainees did not start ART in jail; therefore screening may not increase pharmacy costs
for jails. Detainees newly diagnosed with HIV in jails can be effectively linked to community resources. Jail-based HIV testing
should be a cornerstone of ‘‘test and treat’’ strategies.
Funding
Authors are supported by the following HRSA grants: Dr. Altice: H97HA08541; Dr. Avery: H97HA08543; Dr. Williams: H97HA085xx; Dr. Beckwith:
H97HA08535; and Dr. Spaulding: U90HA07632; Dr. Ball worked as a subcontractor under this grant. Frederick Altice was also supported by a National Institutes on
Drug Abuse for career development award (K24 DA017072). Curt Beckwith was also supported by a National Institute on Drug Abuse grant (K23DA021095) and
the Lifespan/Tufts/Brown Center for AIDS Research grant (P30AI42853). Alex de Voux, Lauren Messina and Anne Spaulding would like to acknowledge support
from the Emory Center for AIDS Research (P30AI050409).
History
Publisher Statement
2012 de Voux et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.